Geron Corporation

Geron Corporation is a commercial-stage biopharmaceutical company based in Foster City, California, with 356 employees. The company generates $3 million in annual revenue. Geron focuses on developing innovative therapies for blood cancers, particularly myelodysplastic syndromes (MDS) and myelofibrosis. Their lead product is a first-in-class telomerase inhibitor, which has received FDA approval for treating adults with low-to-intermediate-1 risk MDS and transfusion-dependent anemia. Additionally, Geron is conducting clinical trials evaluating the effectiveness of their telomerase inhibitor in treating JAK-inhibitor relapsed/refractory myelofibrosis and other hematologic malignancies. Geron's therapeutic approach centers on inhibiting telomerase activity, an enzyme known to be overactive in malignant stem and progenitor cells within the bone marrow. By targeting telomerase, Geron aims to curb the proliferation and induce the death of cancerous cells. For more information about Geron Corporation and its research, please visit www.geron.com.